XOMA Corporation
General ticker "XOMAP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $325.7M (TTM average)
XOMA Corporation follows the US Stock Market performance with the rate: 0.9%.
Estimated limits based on current volatility of 0.2%: low 25.41$, high 25.51$
Factors to consider:
- Company pays dividends (irregularly): last record date 2026-04-02, amount 0.54$ (Y2.12%)
- Total employees count: 13 (0.0%) as of 2024
- US accounted for 42.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operational and conduct risks, Dependence on product success, Integration challenges, External disruptions, Licensing risks
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [19.65$, 32.28$]
- 2026-12-31 to 2027-12-31 estimated range: [21.02$, 34.16$]
Financial Metrics affecting the XOMAP estimates:
- Positive: with PPE of 14.4 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 21.83 > 18.39
- Negative: negative Industry operating income (median)
- Positive: Return on assets ratio (scaled to [-100,100]) of 10.42 > 6.06
- Negative: -0.16 < Industry inventory ratio change (median), % of 0
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of -13.66 <= 0
- Positive: -0.02 < Operating cash flow per share per price, % of 0.60
Short-term XOMAP quotes
Long-term XOMAP plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $4.76MM | $28.49MM | $52.15MM |
| Operating Expenses | $46.61MM | $68.46MM | $40.77MM |
| Operating Income | $-41.85MM | $-39.98MM | $11.38MM |
| Non-Operating Income | $1.02MM | $20.50MM | $20.43MM |
| Interest Expense | $0.57MM | $13.84MM | $13.03MM |
| R&D Expense | $0.14MM | $2.88MM | $1.71MM |
| Income(Loss) | $-40.83MM | $-19.48MM | $31.82MM |
| Taxes | $0.00MM | $-5.66MM | $0.10MM |
| Net Income(Loss)* | $-40.83MM | $-13.82MM | $31.71MM |
| Stockholders Equity | $88.72MM | $81.92MM | $83.94MM |
| Assets | $234.30MM | $221.28MM | $272.70MM |
| Operating Cash Flow | $-18.16MM | $-13.75MM | $2.87MM |
| Capital expenditure | $0.02MM | $0.02MM | $0.00MM |
| Investing Cash Flow | $-0.71MM | $-28.26MM | $50.89MM |
| Financing Cash Flow | $120.59MM | $-11.13MM | $-26.46MM |
| Earnings Per Share** | $-3.56 | $-1.18 | $1.76 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.